Plasmacellular differentiation in extranodal marginal zone B cell lymphomas of the ocular adnexa: An analysis of the neoplastic plasma cell phenotype and its prognostic significance in 136 cases

British Journal of Ophthalmology

Volumn 89, Issue 3, 2005, Pages 352-359

  Coupland, S E ^a   Hellmich, M ^b,c   Auw Haedrich, ^a   Lee, W R ^d   Anagnostopoulos, I ^d   Stein, H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; IMMUNOGLOBULIN; PROTEIN; SYNDECAN 1; TRANSCRIPTION FACTOR PAX5;

ADNEXA DISEASE; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CELL DIFFERENTIATION; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS;

ADP-RIBOSYL CYCLASE; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD38; AUTOANTIGENS; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CREB-BINDING PROTEIN; DNA-BINDING PROTEINS; EYE NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTORS; LYMPHOMA, B-CELL; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR PROTEINS; PLASMA CELLS; PROGNOSIS; PROTEOGLYCANS; RETROSPECTIVE STUDIES; SYNDECAN-1; SYNDECANS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 14744271678     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2004.047092     Document Type: Article

References (43)

1. Auw-Haedrich C, Coupland SE, Kapp A, et al. Long term outcome of ocular adnexal lymphoma subtyped according to trie REAL classification. Br J Ophthalmol 2001;85:63-9.
2. Coupland SE, Krause L, Delecluse HJ, et al. Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases. Ophthalmology 1998;105:1430-41.
3. Hardman-Lea S, Kerr-Muir M, Wotherspoon AC, et al. Mucosal-associated lymphoid tissue lymphoma of the conjunctiva. Arch Ophthalmol 1994;112:1207-12.
4. Jenkins C, Rose GE, Bunce C, et al. Histological features of ocular adnexal lymphoma (REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol 2000;84:907-13.
5. Mannami T, Yoshino T, Oshima K, et al. Clinical, histopathological, and immunogenetic analysis of ocular adnexal lymphoproliferative disorders: characterization of malt lymphoma and reactive lymphoid hyperplasia. Mod Pathol 2001;14:641-9.
6. Nakata M, Matsuno Y, Katsumata N, et al. Histology according to the Revised European-American Lymphoma Classification significantly predicts the prognosis of ocular adnexal lymphoma. Ocular Lymphoma 1999;32:533-43.
7. White WL, Ferry JA, Harris NL, et al. Ocular adnexal lymphoma. A clinicopathologic study with identification of lymphomas of mucosa-associated lymphoid tissue type. Ophthalmology 1995;102:1994-2006.
8. Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours, tumours of haematopoietic and lymphoid tissues, pathology and genetics. Lyons: IARC Press, 2001.
9. Isaacson PG. Mucosa-associated lymphoid tissue lymphoma. Sem Hematol 1999;36:139-47.
10. Salhony KE, Pietra GG. Extranodal lymphoid disorders. Am J Clin Pathol 1993;99:472-85.
11. Baldini L, Blini M, Guffanti A, et al. Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. Ann Oncol 1998;9:779-81.
12. Coupland SE, Hummel M, Stein H. Ocular adnexal lymphomas: five case presentations and a review of the literature. Surv Ophthalmol 2002;47:470-90.
13. Harris NL, Isaacson PG. What are the criteria for distinguishing MALT from non-MALT lymphoma at extranodal sites? Am J Clin Pathol 1999;111:S126-32.
14. Isaacson PG, Norton AJ. Extranodal lymphomas. London: Churchill Livingstone, 1994.
15. Chang CC, Lorek J, Sabath DE, et al. Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. Blood 2002;100:4671-5.
16. Papamichael D, Norton AJ, Foran JM, et al. Immunocytoma: a retrospective analysis from St. Bartholomew's Hospital-1972 to 1996. J Clin Oncol 1999;17:2847-53.
17. Richards MA, Hall PA, Gregory WM, et al. Lymphoplasmacytoid and small cell centrocytic non-Hodgkin's lymphoma-a retrospective analysis from St Bartholomew's Hospital 1972-1986. Hematol Oncol 1989;7:19-35.
18. Norton AJ, Jordan S, Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 1994;173:371-9.
19. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-80.
20. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-29.
21. Coupland SE, Hellmich M, Auw-Haedrich C, et al. Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. Graefes Arch Clin Exp Ophthalmol 2004;242:130-45.
22. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361-92.
23. Sebestyen A, Kovalszlcy I, Mihalik R, et al. Expression of syndecan-1 in human B cell chronic lymphocytic leukaemia. Eur J Cancer 1997;33:2273-7.
24. Tsuboi K, Iida S, Inagaki H, et al. MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. Leukemia 2000;14:449-56.
25. MacLennan IC. Germinal centers. Annu Rev Immunol 1994;12:117-39.
26. MacLennan IC, Casamayor-Palleja M, Toellner KM, et al. Memory B-cell clones and the diversity of their members. Sem Immunol 1997;9:229-34.
27. Barberis A, Widenhorn K, Vitelli L, et al. A novel B-cell lineage-specific transcription factor present at early but not late stages of differentiation. Genes Dev 1990;4:849-59.
28. Jego G, Robillard N, Puthier D, et al. Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells. Blood 1999;94:701-12.
29. Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul 1989;1:27-35.
30. Mehta K, Shahid U, Malavasi F. Human CD38, a cell-surface protein with multiple functions. Faseb J 1996;10:1408-17.
31. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000;95:2084-92.
32. Almeida J, Orfao A, Mateo G, et al. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance. Pathol Biol (Paris) 1999;47:119-27.
33. Dogan A, Bagdi E, Munson P, et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 2000;24:846-52.
34. Fernandez JE, Deaglio S, Donati D, et al. Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues. J Biol Regul Homeost Agents 1998;12:81-91.
35. Keyhani A, Huh YO, Jendiroba D, et al. Increased CD38 expression is associated with favorable prognosis in adult acute leukemia. Leuk Res 2000;24:153-9.
36. Rawstron A, Barrans S, Blythe D, et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol 1999;104:138-43.
37. Natkunam Y, Warnke RA, Montgomery K, et al. Analysis of MUM1/IRF4 protein expression using tissue microorrays and immunohistochemistry. Modern Pathol 2001;14:686-94.
38. Coupland SE, Foss HD, Hidayat AA, et al. Extranodal marginal zone B cell lymphomas of the uvea: an analysis of 13 cases. J Pathol 2002;197:333-40.
39. Jakobiec FA, Knawles DM. An overview of ocular adnexal lymphoid tumors. Trans Am Ophthalmol Soc 1989;87:420-42, discussion 442-4.
40. Johnson TE, Tse DT, Byrne GE Jr, et al. Ocular-adnexal lymphoid tumors: a clinicopathologic and molecular genetic study of 77 patients. Ophthal Plast Reconstr Surg 1999;15:171-9.
41. Knowles DM, Jakobiec FA, McNally L, et al. Lymphoid hyperplasia and malignant lymphoma occurring in the ocular adnexa (orbit, conjunctiva, and eyelids): a prospective multiparametric analysis of 108 cases during 1977 to 1987. Hum Pathol 1990;21:959-73.
42. Sigelman J, Jakobiec FA. Lymphoid lesions of the conjunctiva: relation of histopathology to clinical outcome. Ophthalmology 1978;85:818-43.
43. Knowles DM, ed. Neoplastic hematopathology. Chapter 35. Philadelphia: Lippincott Williams and Wilkins, 2000.